| scholarly article | Q13442814 |
| P2093 | author name string | Hideki Fujii | |
| Hiroki Ishikawa | |||
| Kohichiroh Yasui | |||
| Kanji Yamaguchi | |||
| Taichiro Nishikawa | |||
| Hiroyuki Kimura | |||
| Yoshito Itoh | |||
| Hideki Nakamura | |||
| Atsushi Umemura | |||
| Michihisa Moriguchi | |||
| Toshihide Shima | |||
| Masahito Minami | |||
| Saiyu Tanaka | |||
| Shiro Takami | |||
| Yasuyuki Nagao | |||
| P2860 | cites work | Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 |
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors | Q34513827 | ||
| Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. | Q34638767 | ||
| Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection | Q35044909 | ||
| Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. | Q36148043 | ||
| Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study | Q36723956 | ||
| The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection | Q38113079 | ||
| Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response | Q38904167 | ||
| Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis | Q38946893 | ||
| Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. | Q40791170 | ||
| Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. | Q41041935 | ||
| Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study | Q42210312 | ||
| Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial | Q42224933 | ||
| Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies | Q42231673 | ||
| Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection | Q42232746 | ||
| Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment | Q42286521 | ||
| Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy | Q42978970 | ||
| Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay | Q42985837 | ||
| Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. | Q42993815 | ||
| Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders | Q43041150 | ||
| Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). | Q50559989 | ||
| FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest | Q62658359 | ||
| P433 | issue | 25 | |
| P921 | main subject | daclatasvir | Q5207712 |
| P304 | page(s) | 1064-1072 | |
| P577 | publication date | 2017-09-01 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions | |
| P478 | volume | 9 |
| Q59360673 | Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world |
| Q90682026 | Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China |
| Q58780610 | Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients |
| Q53685592 | Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. |
Search more.